📊 LONA Key Takeaways
Is LeonaBio, Inc. (LONA) a Good Investment?
LeonaBio is a pre-revenue development-stage biotech company with -$105.6M net income and -$45.7M operating cash burn, indicating no commercialized products generating meaningful revenue. While the company maintains a strong cash position ($69.3M) with zero debt, at the current burn rate the runway extends only ~1.5 years without additional capital raises, creating material financing risk and execution pressure.
LeonaBio is pre‑revenue with deep operating and net losses alongside extremely negative ROE/ROA, indicating poor capital efficiency and no demonstrated path to profitability. While liquidity is acceptable and leverage is minimal, the current cash balance supports only a limited runway given the magnitude of cash burn, implying likely financing/dilution risk absent rapid progress toward revenue or material cost cuts.
Why Buy LeonaBio, Inc. Stock? LONA Key Strengths
- Strong cash reserves of $69.3M provide runway for continued R&D
- Zero debt with clean balance sheet (Debt/Equity 0.00x)
- Healthy liquidity position (1.88x current ratio) to meet short-term obligations
- $69.3M cash provides near‑term liquidity
- Zero long‑term debt and 0.00x debt/equity reduce solvency risk
- Current and quick ratios of 1.88x indicate adequate short‑term coverage
LONA Stock Risks: LeonaBio, Inc. Investment Risks
- Pre-revenue or minimal revenue status with no clear path to profitability demonstrated
- Significant annual cash burn of -$45.7M with persistent operating losses of -$102.3M
- Cash runway exhaustion risk requiring dilutive capital raise within 18-24 months at current burn
- Flat net income improvement YoY (+0.0%) suggests structural burn continues unabated
- Development-stage biotech carries binary product development and commercialization risk
- No revenue; business viability not yet validated
- High cash burn (OCF -$45.7M; operating loss -$102.3M) implies dilution/financing risk within ~1–2 years
- Extremely negative ROE (-380%) and ROA (-114.6%) signal poor capital efficiency and potential going‑concern pressure
Key Metrics to Watch
- Revenue generation and gross margin upon product commercialization
- Operating cash burn rate trends and impact on runway
- Capital raise activity and dilution impact
- Product development milestones and regulatory approval progress
- Insider transaction patterns for signals of management confidence
- Operating cash flow (burn rate)
- Cash & equivalents (runway)
LeonaBio, Inc. (LONA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
LeonaBio, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LONA Profit Margin, ROE & Profitability Analysis
LONA vs Healthcare Sector: How LeonaBio, Inc. Compares
How LeonaBio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LeonaBio, Inc. Stock Overvalued? LONA Valuation Analysis 2026
Based on fundamental analysis, LeonaBio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LeonaBio, Inc. Balance Sheet: LONA Debt, Cash & Liquidity
LONA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: LeonaBio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-25.19 indicates the company is currently unprofitable.
LONA Revenue Growth, EPS Growth & YoY Performance
LeonaBio, Inc. Dividends, Buybacks & Capital Allocation
LONA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for LeonaBio, Inc. (CIK: 0001620463)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 13, 2026 | 4 | xslF345X06/form4-04132026_080418.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/form4-04132026_080410.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/form4-04132026_080453.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/form4-04132026_080428.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/form4-04132026_080426.xml | View → |
❓ Frequently Asked Questions about LONA
What is the AI rating for LONA?
LeonaBio, Inc. (LONA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LONA's key strengths?
Claude: Strong cash reserves of $69.3M provide runway for continued R&D. Zero debt with clean balance sheet (Debt/Equity 0.00x). ChatGPT: $69.3M cash provides near‑term liquidity. Zero long‑term debt and 0.00x debt/equity reduce solvency risk.
What are the risks of investing in LONA?
Claude: Pre-revenue or minimal revenue status with no clear path to profitability demonstrated. Significant annual cash burn of -$45.7M with persistent operating losses of -$102.3M. ChatGPT: No revenue; business viability not yet validated. High cash burn (OCF -$45.7M; operating loss -$102.3M) implies dilution/financing risk within ~1–2 years.
What is LONA's revenue and growth?
LeonaBio, Inc. reported revenue of N/A.
Does LONA pay dividends?
LeonaBio, Inc. does not currently pay dividends.
Where can I find LONA SEC filings?
Official SEC filings for LeonaBio, Inc. (CIK: 0001620463) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LONA's EPS?
LeonaBio, Inc. has a diluted EPS of $-24.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LONA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LeonaBio, Inc. has a SELL rating with 77% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LONA stock overvalued or undervalued?
Valuation metrics for LONA: ROE of -380.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LONA stock in 2026?
Our dual AI analysis gives LeonaBio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LONA's free cash flow?
LeonaBio, Inc.'s operating cash flow is $-45.7M, with capital expenditures of $33.0K.
How does LONA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -380.0% (avg: 15%), current ratio 1.88 (avg: 2).